Latest News

2 February 2016

Targeted DEP™ shows sustained superior performance

Starpharma today announced the final results of the preclinical study of its HER2-targeted DEP™ conjugate, which achieved complete tumour regression at the last study time point of 120 days post dosing.

Read more

28 January 2016

Appendix 4C - Quarterly Cashflow Report

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 December 2015.

Read more

20 January 2016

Starpharma raises $1.9M under Share Purchase Plan

Starpharma announced it has completed its Share Purchase Plan (SPP) having raised approximately $1.9 million. Combining the SPP with the recent institutional placement which raised $32 million (before costs); the Company has successfully raised a total of approximately $34 million at $0.73 per share.

Read more

16 December 2015

Starpharma signs MOU for VivaGel condom in China

Starpharma announced today that it has signed a Memorandum of Understanding (MOU) with a Chinese company who is a major provider of condoms to the Chinese government.  The MOU outlines the key commercial and other terms for Starpharma’s partner to manufacture and sell a VivaGel® coated condom to the Government segment of the Chinese market.

Read more

In the media

17 December 2015

The Age: Starpharma set for condom sales in China

"Starpharma has signed a memorandum of understanding with a Chinese company to make and sell its VivaGel-coated condom in China...The Chinese company is a major supplier of condoms to the Chinese government's Birth Control Department and Disease Prevention Department. The so-called government market in China requires about three billion condoms each year for birth control and disease prevention."

Go to the article (external link)

17 November 2015

The Australian: Cancer trial results prove good medicine for biotech's stocks

The Australian's Sarah-Jane Tasker reports that "Starpharma's shares have hit a fresh high following positive results in a preclinical trail for its ovarian cancer model. The company said a cancer drug treatment coupled with its dendrimer (DEP) technology - which allows for more effective drug delivery - had resulted in complete tumour regression and 100 per cent survival in a preclinical trial done on mice."

Go to the artice (external link)

24 September 2015

The Australian: Starpharma wins EU approval for VivaGel

The Australian reports that "Starpharma has been granted approval to market its VivaGel BV in the European Union's 28 member countries, where more than 260 million women live. The lubricant treats bacterial vaginosis (BV), the most common vaginal infection experienced by women around the world".

Go to the article (external link)

17 September 2015

The Wall Street Journal/The Australian: Australia looks to health care as a remedy for resource slump doldrums

The Wall Street Journal's Rachel Pannett comments that 'Australia is taking a page from Silicon Valley's playbook as it seeks to reinvigorate its resource-dependent economy at the end of a long commodities boom, placing bets on biotechnology and digital health care'. Tax incentives for R&D have moved Australia to fourth place globally for biotechnology innovation, with a further boost expected following a change of Prime Minister from Tony Abbott to Malcolm Turnbull. Starpharma is featured in the article for its drug delivery technology and recent licensing deal with AstraZeneca.

Go to the article (external link)

Shareholder Updates

30 October 2015

Appendix 4C - Quarterly Cashflow Report

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 September 2015.

Read more

29 October 2015

Shareholder Update October 2015

In this Issue:

› EU marketing approval granted for VivaGel® BV
› Multi-product DEP® license with AstraZeneca
› VivaGel® BV: Symptomatic Relief and Treatment of BV/Prevention of recurrence
› VivaGel® condom
› Phase 1 DEP® docetaxel trial update                                                                                    

› Agrochemicals
› Starpharma in the News
› Starpharma full year financial results      

› Presentations and conferences

Download: Shareholder Update October 2015 (pdf file, 994kb)

Sign up to receive news here

© Starpharma Holdings Limited 2016